FDA 483 - CSL Plasma Inc. - November 18, 2019

An FDA inspection of CSL Plasma, Inc. in Jackson, MS, a plasma center, revealed significant deficiencies in following written standard operating procedures. Observations included failures to properly handle damaged products and delays in reviewing critical error management issues. Additionally, the firm failed to adequately separate labeling operations, creating a risk of mix-ups.